Arbutus Biopharma Corp (ABUS) Stock Price & Analysis
Arbutus Biopharma Corp (ABUS) — MoonshotScore 49/100 (Fair band), calculated Nov 18, 2026. Price $4.02 (-1.23%), as of the Nov 20, 2026 trading session; market cap $616M.
Educational signal · not a buy or sell recommendation · How to read this
Arbutus Biopharma Corp · ABUS · NASDAQ
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Arbutus Biopharma (ABUS)
FairWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality, a fortress balance sheet and elite growth, at a dirt-cheap price. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Elite; Financial Safety: Fortress; Valuation: Cheap; Growth Durability: Compounding; Momentum: Rising.
- EPS beat 2 of the last 4 reports
- Altman Z -0.28 · Piotroski F 7
- ROE 91.0% · ROA 55.9% · current ratio 81.42 · earnings yield 21.2% · free-cash-flow yield -3.4%
Helping: business quality, balance-sheet strength, an attractive price, durable growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 61 | Fair | |
| 54 | Fair | |
| 54 | Fair | |
| 49 | Fair | |
| 49 | Fair | |
| 49 | Fair |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $4.02 | |
| Change on the day | -1.23% | |
| 52-week range | $3.50 – $5.45 | |
| Market capitalisation | $616M | — |
| Price / earnings (trailing) | 3.58 | |
| Shares traded on the day | 2.99M |
Price & events
Other perspectives
Council score for Arbutus Biopharma (ABUS): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 18, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Arbutus Biopharma (ABUS), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Arbutus Biopharma Corp (ABUS) is listed on NASDAQ. It employs 19 people and is led by Lindsay Androski. The market values it at $616M.
What do the latest results show for Arbutus Biopharma (ABUS)?
Short answer · as of
Against analyst estimates the company has EPS beat 2 of the last 4 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $529,000 | -$8M | -$0.04 (diluted) |
| Q4 FY2025 | $1M | -$4M | — |
| Q1 FY2026 | $179M | $170M | $0.87 (diluted) |
| Q2 FY2026 | $1M | -$5M | -$0.03 (diluted) |
What are the financial strengths and risks for Arbutus Biopharma (ABUS)?
Short answer
The MoonshotScore pillars rate business quality, balance-sheet strength, an attractive price, durable growth as strengths. The distress and quality screens read Altman Z -0.28 · Piotroski F 7. Trailing ratios: ROE 91.0% · ROA 55.9% · current ratio 81.42 · earnings yield 21.2% · free-cash-flow yield -3.4%.
How does Arbutus Biopharma compare with its peers?
Short answer
Arbutus Biopharma's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $12.85 Nov 20, 2026 | $1.40B | 97 5-pillar Nov 18, 2026 | |
| $18.41 Nov 20, 2026 | $1.31B | 96 5-pillar Nov 18, 2026 | |
| $8.76 Nov 20, 2026 | $521M | 91 5-pillar Nov 18, 2026 | |
| $13.45 Nov 19, 2026 | $475M | 91 5-pillar Nov 18, 2026 | |
| $40.09 Nov 20, 2026 | $755M | 88 5-pillar Nov 18, 2026 | |
| $46.63 Nov 20, 2026 | $1.39B | 76 5-pillar Nov 18, 2026 | |
| $11.54 Nov 20, 2026 | $817M | 69 5-pillar Nov 18, 2026 | |
| $38.85 Nov 20, 2026 | $1.26B | 69 5-pillar Nov 18, 2026 | |
| $9.19 Nov 20, 2026 | $540M | 68 5-pillar Nov 18, 2026 | |
| $19.19 Nov 20, 2026 | $1.18B | 66 5-pillar Nov 18, 2026 | |
| $30.43 Nov 20, 2026 | $1.02B | 64 5-pillar Nov 18, 2026 | |
| $7.98 Nov 20, 2026 | $780M | 63 5-pillar Nov 18, 2026 | |
| Arbutus Biopharma (ABUS) — this page | $4.02 | $616M | 49 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 1, 2026
- Transactions
- 26
- Identified insiders
- 4
- Purchases
- 0
- Sales
- 0
- Other transactions
- 26
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ABUS in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported ABUS in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Arbutus Biopharma (ABUS)?
What Investors Ask About Arbutus Biopharma (ABUS)
These answers are editorial: 1 of these 9 answers is drawn from the ABUS research dossier (written May 9, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for ABUS?
ABUS carries the MoonshotScore stated above — the Fair band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is ABUS a good stock to buy?
Stock Expert AI does not rate ABUS buy, sell or hold. Arbutus Biopharma Corp carries a MoonshotScore, in the Fair band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the ABUS stock price today?
The last price recorded for Arbutus Biopharma Corp (ABUS), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for ABUS?
The main risks for Arbutus Biopharma Corporation (ABUS) include the potential for clinical trial failures, competition from other pharmaceutical and biotechnology companies, and regulatory hurdles and delays. The company's high dependence on clinical trial success and negative profit margin also pose significant risks.
What are the key factors to evaluate for ABUS?
Arbutus Biopharma Corp (ABUS) holds a MoonshotScore in the low range. To weigh it, start with the trailing P/E under Price & valuation on this page. Strategic partnerships can provide Arbutus with access to new markets and revenue streams. Not financial advice.
How frequently does ABUS data refresh on this page?
ABUS's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven ABUS's recent stock price performance?
Arbutus Biopharma Corp (ABUS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary RNAi technology platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ABUS overvalued or undervalued right now?
The trailing P/E of Arbutus Biopharma Corp (ABUS) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of ABUS?
Fractional-share availability for Arbutus Biopharma Corp (ABUS) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 14 figures on this page — 7 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com